Next Article in Journal
Trajectory of End-of-Life Pain and Other Physical Symptoms among Cancer Patients Receiving Home Care
Previous Article in Journal
A Canadian Perspective on the Challenges for Delivery of Curative-Intent Therapy in Stage III Unresectable Non-Small Cell Lung Cancer
Open AccessArticle

Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome

1
Department of Nuclear Medicine, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Jette, Belgium
2
Department of Medical Oncology, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Jette, Belgium
*
Authors to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(3), 1630-1640; https://doi.org/10.3390/curroncol28030152
Received: 29 March 2021 / Revised: 19 April 2021 / Accepted: 24 April 2021 / Published: 27 April 2021
(This article belongs to the Section Medical Oncology)
PD-1 Immune checkpoint inhibitors, such as Pembrolizumab, can have a durable beneficial therapeutic effect in patients with advanced melanoma. However, not all patients will benefit equally from these therapies, and (potentially life-threatening) immune-related adverse events may occur. In this study, we investigate the value of early response assessment by FDG-PET/CT as a biomarker for predicting survival. We identified all patients with advanced melanoma who were treated with Pembrolizumab in our medical center and underwent a baseline and at least one follow-up FDG-PET/CT. The total metabolic tumor volume (TMTV) was calculated, and the evolution was compared to survival parameters. A total of 77 patients underwent a baseline and at least one follow-up FDG-PET/CT, 36 patients had follow-up imaging within 2–4 months, and 21 patients an FDG-PET/CT 5–6 months after baseline. When the TMTV evolution was categorized into two subgroups (stable/decrease versus increase), an association was found between stability or decrease in TMTV and better PFS and OS. A similar trend, however non-significant, was observed at 5–6 months. The evolution in TMTV as assessed by FDG-PET/CT 2–4 months after treatment initiation is associated with long-term outcomes in patients with advanced melanoma treated with Pembrolizumab. View Full-Text
Keywords: Pembrolizumab; PET/CT; melanoma Pembrolizumab; PET/CT; melanoma
Show Figures

Figure 1

MDPI and ACS Style

Vermeulen, S.; Awada, G.; Keyaerts, M.; Neyns, B.; Everaert, H. Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome. Curr. Oncol. 2021, 28, 1630-1640. https://doi.org/10.3390/curroncol28030152

AMA Style

Vermeulen S, Awada G, Keyaerts M, Neyns B, Everaert H. Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome. Current Oncology. 2021; 28(3):1630-1640. https://doi.org/10.3390/curroncol28030152

Chicago/Turabian Style

Vermeulen, Sim; Awada, Gil; Keyaerts, Marleen; Neyns, Bart; Everaert, Hendrik. 2021. "Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome" Curr. Oncol. 28, no. 3: 1630-1640. https://doi.org/10.3390/curroncol28030152

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop